Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
NEO · Nasdaq · United States · Services-Testing Laboratories
In shortNEOGENOMICS INC is loss-making, burns cash and carries moderate debt, with revenue growing (+10.1% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -15.9% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -14.9% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -12.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -9.6% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.26× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.41× | 88/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -30.88× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.46 | 9/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -3.0% | 8/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 4.0% | 96/100 |
| Operating margin volatility | 7.0% | 46/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 12.6% | 87/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 484 | 510 | 592 | 661 | 727 |
| Cost of revenue | 297 | 322 | 347 | 370 | 413 |
| Gross profit | 187 | 188 | 245 | 290 | 314 |
| Research & development | 22 | 30 | 27 | 31 | 37 |
| Operating income | (119) | (158) | (108) | (92) | (116) |
| Interest expense | 8.2 | 7.6 | 6.9 | 6.6 | 3.8 |
| Pre-tax income | (15) | (159) | (97) | (81) | (110) |
| Income tax | (6.7) | (15) | (9.1) | (1.9) | (2.2) |
| Net income | (8.3) | (144) | (88) | (79) | (108) |
| Diluted shares (millions) | 120 | 124 | 126 | 127 | 128 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
1.46 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 28, 2026